Carol Abel joins FMI as VP education and research
ARLINGTON, Va. A former executive at the American Pharmacists Association has joined the Food Marketing Institute to develop and execute the organization’s education programs and research initiatives.
Carol Abel was named FMI’s VP education and research. Abel comes to FMI from the American Pharmacists Association where she most recently served as senior director of education strategy and compliance officer. She was responsible for the association’s pharmacy accreditation program, continuing education best practices, standards and new initiatives. She also served as director of education for the association.
“As provided in the new FMI strategic plan approved earlier this year by the board of directors, we are laser-focused on enhancing our industry education programming and expanding opportunities in leadership development for those who work in our member companies,” said FMI president and CEO Leslie Sarasin. “Carol has an impressive background and extensive expertise, and her previous success in identifying innovative educational strategies makes her a welcome addition to the FMI team.”
Cirrus targets ear-ringing with Tinnitex
COLD SPRING HARBOR, N.Y. Cirrus Healthcare Products has expanded its ear care offerings with a new product, slated to hit retail shelves in spring 2011.
Tinnitex is the first and only earplug to help relieve tinnitus, a condition that causes ringing in the ears, the company said. According to the Journal of Clinical Nursing, more than 50 million Americans suffer from tinnitus.
“Tinnitex gives the suffering consumer an option to the inconvenience of ear drops or the excessive amount of pills that consumers are tired of taking. The Tinnitex earplug is easy to apply and comfortable to wear and, at about $10 at retail for six pairs, provides affordable relief,” said Cirrus CEO Drew O’Connell.
GSK Consumer Healthcare to FDA: Smoke out smokeless tobacco products
PARSIPPANY, N.J. GlaxoSmithKline Consumer Healthcare is urging the Food and Drug Administration to remove smokeless tobacco products from the market.
GSK Consumer Healthcare, which manufactures such nicotine-replacement therapy products as Nicorette and NicoDerm CQ, submitted a comment to the FDA on the potential public health impact of oral dissolvable tobacco products, "calling for such products to be withdrawn from the market until their sponsors can demonstrate to [the FDA] that their marketing is appropriate for the protection of public health," the company noted in a release Tuesday.
The announcement comes after the American Heart Association issued a policy statement on smokeless tobacco products, which said that such products are not safe alternatives to smoking and are associated with heart attack, stroke and certain cancers.
GSK Consumer Healthcare also said that it is committed to working with the FDA, in addition to medical and clinical experts to make smoking-cessation products safe and available for consumers.